Reply to E. Hindié

Alexander M M Eggermont¹, Christian U Blank¹, Mario Mandala¹+28

• ¹Alexander M. M. Eggermont, MD, PhD, Princess Máxima Center, Utrecht, the Netherlands; Christian U. Blank, MD, PhD, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands; Mario Mandala, MD, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Georgina V. Long, BSc, MBBS, Melanoma Institute Australia, The University of Sydney, and Mater and Royal North Shore Hospitals, Sydney, New South Wales, Australia; Victoria G. Atkinson, MBBS, Princess Alexandra Hospital, Brisbane, Queensland, Australia; St 00B4ephane Dalle, MD, PhD, Hospices Civils de Lyon Cancer Institute, Lyon, France; Andrew M. Haydon, MBBS, PhD, Alfred Hospital, Melbourne, Victoria, Australia; Andrey Meshcheryakov, MD, PhD, N.N. Blokhin Cancer Research Center, Moscow, Russian Federation; Adnan Khattak, MD, Fiona Stanley Hospital and Edith Cowan University, Perth, Western Australia, Australia; Matteo S. Carlino, BMedSc, MBBS, Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney, New South Wales, Australia; Shahneen Sandhu, MD, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; James Larkin, PhD, Royal Marsden Hospital, London, United Kingdom; Susana Puig, MD, PhD, Hospital Clinic Universitari de Barcelona, Barcelona, Spain; Paolo A. Ascierto, MD, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale," Naples, Italy; Piotr Rutkowski, MD, PhD, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Dirk Schadendorf, MD, PhD, University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany; Rutger Koornstra, MD, PhD, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands; Leonel Hernandez-Aya, MD, Washington University School of Medicine, St Louis, MO; Anna Maria Di Giacomo, MD, Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy; Alfonsus J. M. van den Eertwegh, MD, PhD, Amsterdam University Medical Center, location VUMC, Amsterdam, the Netherlands; Jean-Jacques Grob, MD, Aix Marseille University, Hôpital de la Timone, Marseille, France; Ralf Gutzmer, MD, Skin Cancer Center, Hannover Medical School, Hanover, Germany; Rahima Jamal, MD, BSc, Centre Hospitalier de l'Université de Montreal (CHUM), Centre de recherche du CHUM, Montreal, Quebec, Canada; Paul C. Lorigan, MD, Christie NHS Foundation Trust, Manchester, United Kingdom; Alexander C. J. van Akkooi, MD, PhD, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands; Clemens Krepler, MD, Merck & Co, Inc, Kenilworth, NJ; Nageatte Ibrahim, MD, Merck & Co, Inc, Kenilworth, NJ; Sandrine Marreaud, MD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Michal Kicinski, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Stefan Suciu, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Caroline Robert, MD, PhD, Gustave Roussy and Paris-Saclay University, Villejuif, France.